Fed. Circ. Denies Longer Patent Term For Pfizer Cancer Drug
The Federal Circuit on Friday ruled that the U.S. Patent and Trademark Office correctly refused to extend the term of a cancer treatment patent issued to a Pfizer unit by nearly...To view the full article, register now.
Already a subscriber? Click here to view full article